Standardizing Aminoglycoside Induced Ototoxicity Monitoring

Authors

Claire Elson, Children's Mercy HospitalFollow
Christopher M. Oermann, Children's Mercy HospitalFollow
Stephanie Duehlmeyer, Children's Mercy HospitalFollow
Ellen Meier, Children's Mercy HospitalFollow

Publication Date

11-2019

Files

Abstract

Aminoglycoside (AG) antibiotics are essential for the treatment of cystic fibrosis (CF) lung infections. Pseudomonas aeruginosa. Nontuberculous mycobacteria. Monitoring is critical secondary to potential nephrotoxicity and ototoxicity. Children’s Mercy Kansas City (CMKC), standardized nephrotoxicity monitoring in 2016. Observed variable ototoxicity monitoring practices. Prevalence of ototoxicity, 2016 CFF Patient Registry, 1.1% in pediatric patients (less than or equal to 18 years). 2.2% in pediatric and adult population. National Institute of Deafness and Other Communication Disorders, 13% in US population equal to or less than 12 years old. A standardized AG induced ototoxicity monitoring algorithm (AIOA) was developed and implemented at CMKC in 2017.

Disciplines

Pediatrics | Pharmacy and Pharmaceutical Sciences | Pulmonology

Notes

Presented at the North American Cystic Fibrosis Conference; Nashville, TN; October 31- November 2nd, 2019.

Recommended Citation

Elson, Claire; Oermann, Christopher M.; Duehlmeyer, Stephanie; and Meier, Ellen, "Standardizing Aminoglycoside Induced Ototoxicity Monitoring" (2019). Posters. 254.
https://scholarlyexchange.childrensmercy.org/posters/254